Heron’s stock rises after FDA approval of surgical medicine

Shares of Heron Therapeutics Inc. gained 3.0% in trading on Thursday after the company said the Food and Drug Administration had approved its non-opioid anesthetic for use in some surgical patients. The drug, Zynrelef, is expected to become available to hospitals in July. Heron’s stock is down 16.2% for the year, while the S&P 500 is up 8.1%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.